Ocugen Q1 2025 net loss $0.05/sh; cash $38.1M; OCU400 Phase 3 on track for mid-2026 BLA/MAA

Ocugen, Inc.

2026-Q1 EPS reported -$0.05 vs consensus -$0.05 ▲ beat (+4.8%)

Cash & restricted cash $38.1M as of Mar 31, 2025, down from $58.8M at Dec 31, 2024; runway into Q1 2026.
Operating expenses $16.0M (R&D $9.5M, G&A $6.5M) vs $13.2M in Q1 2024; net loss per share unchanged at $0.05.
OCU400 Phase 3 liMeliGhT RP trial recruiting; BLA/MAA filings targeted by mid-2026; ATMP classification from EMA.
OCU410ST Phase 2/3 pivotal trial for Stargardt disease to start mid-2025; BLA filing target 2027.
OCU410 for GA: Phase 2 dosing complete; 12-month data shows 4-line VA gain and 41% slower lesion growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.